About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Roser Ferrer Costa
IP: Zamira Vanessa Diaz Riascos
IP: Joan López Hellin
IP: Clara Carnicer Cáceres
IP: M Mar Mañu Pereira Collaborators: Augusto Cesar Sao Aviles, Patricia González Ruiz, Claire Diot, Miguel Chillon Rodriguez, Simon Schwartz Navarro Funding agency: EUROPEAN COMMISSION Funding: 1543050.83 Reference: ERDERA/EC/HLTH-2023-DISEASE-07-01/2023/MAÑU Duration: 01/09/2024 - 31/08/2031
IP: Fernanda Raquel Da Silva Andrade Collaborators: Roser Ferrer Costa, Julia German Cortes, Angels Alcina Mila, Diana Fernandes de Rafael Funding agency: Asociación Española Contra el Cáncer Funding: 10000 Reference: SNRGS247164DASI Duration: 01/06/2024 - 31/05/2026
IP: Roser Ferrer Costa Collaborators: - Funding agency: FUNDACIÓN JOSÉ LUIS CASTAÑO Funding: 0.01 Reference: SECQ/FERRER/2023 Duration: 01/01/2024 - 31/12/2025
IP: Yolanda Villena Ortiz Collaborators: - Funding agency: FUNDACIÓN JOSÉ LUIS CASTAÑO Funding: 6000 Reference: SEQC 001 Duration: 01/07/2023 - 01/07/2024
PMID: 38074506 Journal: JHEP Reports Year: 2024 Reference: JHEP Rep. 2023 Oct 12;6(1):100932. doi: 10.1016/j.jhepr.2023.100932. eCollection 2024 Jan. Impact factor: Publication type: Paper in international publication Authors: Banares, Juan; Barreira-Diaz, Ana; Blanco-Grau, Albert; Buti, Maria; Campins, Magda; Casado, Miguel Angel; Colom, Joan; Dominguez-Hernandez, Raquel; Esteban, Rafael; Falco-Roget, Anna et al. DOI: 10.1016/j.jhepr.2023.100932
PMID: 36986692 Journal: Pharmaceutics Year: 2023 Reference: Pharmaceutics. 2023 Mar 3;15(3):831. doi: 10.3390/pharmaceutics15030831. Impact factor: Publication type: Review in international publication Authors: Abasolo, Ibane; Andrade, Fernanda; German-Cortes, Julia; Rafael, Diana; Vilar-Hernandez, Mireia et al. DOI: 10.3390/pharmaceutics15030831
PMID: 37033229 Journal: Frontiers in Endocrinology Year: 2023 Reference: Front Endocrinol (Lausanne). 2023 Mar 22;14:1129213. doi: 10.3389/fendo.2023.1129213. eCollection 2023. Impact factor: Publication type: Paper in international publication Authors: Aulinas, Anna; Biagetti, Betina; Blanco, Alberto; Carrato, Cristina; Casano-Sancho, Paula; Cordero, Esteban; Gil, Joan; Hostalot, Cristina; Ibanez-Dominguez, Javier; Jorda, Mireia et al. DOI: 10.3389/fendo.2023.1129213
PMID: 37242726 Journal: Pharmaceutics Year: 2023 Reference: Pharmaceutics. 2023 May 12;15(5):1484. doi: 10.3390/pharmaceutics15051484. Impact factor: Publication type: Review in international publication Authors: Arango, Diego; Clark, Simon J; Duran-Lara, Esteban F; Ferrer, Roser; Guerrero, Marcelo; Marican, Adolfo; Rafael, Diana; Sarmento, Bruno; Schwartz, Simo Jr et al. DOI: 10.3390/pharmaceutics15051484
PMID: 37282505 Journal: CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS Year: 2023 Reference: Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231180865. doi: 10.1177/10760296231180865. Impact factor: Publication type: Paper in international publication Authors: Campoy, Desiree; Canals, Tania; Cerezo-Manchado, Juan Jose; Flores, Katia; Herranz, Maria Jose; Johansson, Erik; Martinez, Laia; Olivera, Pavel; Salinas, Ramon; Velasquez-Escandon, Cesar et al. DOI: 10.1177/10760296231180865
PMID: NOPMID0100 Journal: Advances in Laboratory Medicine Year: 2022 Reference: Adv Lab Med / Av en Med Lab. 2022;3(3):263-271. doi:10.1515/almed-2022-0016 Impact factor: Publication type: Paper in national publication Authors: Barquin Del Pino , Raquel ; Benitez Carabante, Maria Isabel ; Casis Saenz, Ernesto; Castellote Bellés, Laura; Ferrer Costa, Roser; López Hellin, Joan; Martinez Sánchez, Luisa; Miarons Font , Marta; Paciucci Barzanti, Rosanna; Rodríguez Frias, Francisco et al. DOI: 10.1515/almed-2022-0016
PMID: PMID0102 Journal: Rare Disease and Orphan Drugs Journal Year: 2022 Reference: Rare Dis Orphan Drugs J. 2022;1(3):13. doi:10.20517/rdodj.2022.09 Impact factor: Publication type: Editorail in international publication Authors: Abasolo, Ibane; Gazeau, Florence; K. A. Silva, Amanda; Sagné, Corinne et al. DOI: 10.20517/rdodj.2022.09
PMID: NOPMID0101 Journal: Ceramics International Year: 2022 Reference: Ceram Int. 2023;49(6):9324-9337. doi:10.1016/j.ceramint.2022.11.099 Impact factor: Publication type: Paper in international publication Authors: Abasolo, Ibane; Bomati-Miguel, Óscar; Felix, Eduardo; Fernández-Ponce, Cecilia; García-Cózar, Francisco; Kriwet, Jürgen; Lahoz, Ruth; Litrán, Rocío; Llaguno-Munive, Monserrat; Mánuel, Jose M et al. DOI: 10.1016/j.ceramint.2022.11.099
PMID: 32143211 Journal: PLoS One Year: 2020 Reference: PLoS One. 2020 Mar 6;15(3):e0230022. doi: 10.1371/journal.pone.0230022. eCollection 2020. Impact factor: Publication type: Paper in international publication Authors: Alsina, Merce; Conesa, Jose Javier; Gil, Silvia; Kamma-Lorger, Christina; Martinez-Esain, Jordi; Martinez-Trucharte, Francesc; Perez-Berna, Ana J; Sabes, Manel; Solano, Eduardo et al. DOI: 10.1371/journal.pone.0230022
PMID: 15380889 Journal: CLINICAL NUTRITION Year: 2004 Reference: Clin Nutr. 2004 Oct;23(5):1001-8. doi: 10.1016/j.clnu.2003.12.006. Impact factor: Publication type: Paper in international publication Authors: Baena-Fustegueras, Juan Antonio; Garcia-Arumi, Elena; Lopez-Hellin, Joan; Riera, Simon Schwartz; Vidal, Montse et al. DOI: 10.1016/j.clnu.2003.12.006
PhD student: Emily Marisol Toscano Guerra Director/s: Rosanna Paciucci Barzanti University: Universitat Autònoma de Barcelona Year: 2023
Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.
